TABLE 1.

Baseline Charactersitics

Baseline Characteristics
	Placebo	Cranberry Juice	P-value
Age	51.4 ± 15.1	44.8 ± 17.5	0.06
Men, No. (%)	11 (25%)	20 (48%)	0.029
Body Mass Index	27.2 ± 5.5	27.7 ± 5.9	0.70
LVEF, %	61.3 ± 5.3	63.0 ± 6.5	0.50
Family history of CAD, No. (%)	15 (34%)	16 (39%)	0.69
Hyperlipidemia, No. (%)	24 (55%)	19 (46%)	0.75
Smoking, No. (%)	2 (5%)	1 (2%)	0.58
Hypertension currently drug treated, No. (%)	11 (25%)	12 (29%)	0.66
Diabetes mellitus, No. (%)	2 (5%)	0 (0%)	0.17
Obesity (BMI>=30), No. (%)	12 (27%)	8 (20%)	0.40
Arrhythmia (afib/SVT/VT), No. (%)	5 (11%)	2 (5%)	0.28
Valve disease, No. (%)	1 (2%)	1 (2%)	0.96
Cerebral Vascular disease, No. (%)	1 (2%)	0 (0%)	0.33
Previous MI, No. (%)	0 (0%)	1 (2%)	0.30
PTCA/Atherectomy/Stent (Angioplasty), No. (%)	0 (0%)	1 (2%)	0.30
CABG Surgery (Coronary Artery Bypass Graft), No. (%)	0 (0%)	1 (2%)	0.30
ACE inhibitor, No. (%)	4 (9%)	3 (8%)	0.77
Aspirin, No. (%)	14 (33%)	9 (23%)	0.31
Calcium blocker, No. (%)	1 (2%)	4 (10%)	0.14
Statins, No. (%)	11 (25%)	11 (28%)	0.79
Omega-3 FA, No. (%)	10 (23%)	6 (15%)	0.34
Any Vitamin (multi/C/E), No. (%)	24 (56%)	18 (45%)	0.32

LVEF, left ventricular ejection fraction; CAD, coronary artery disease; afib, atrial fibrillation; SVT, supraventricular tachycardia; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; ACE, angiotensin converting enzyme; FA, fatty acids